

# WHO Advisory Committee on Variola Virus Research

Report of the Twentieth Meeting

Geneva, Switzerland

26 – 27 September 2018



INFECTIOUS HAZARDS  
MANAGEMENT





# **WHO Advisory Committee on Variola Virus Research**

Report of the Twentieth Meeting

Geneva, Switzerland

26 – 27 September 2018

WHO/WHE/IHM/2019.6

© World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** WHO Advisory Committee on Variola Virus Research: Report of the twentieth meeting, Geneva, Switzerland, 26–27 September 2018: World Health Organization; 2019. (WHO/WHE/IHM/2019.6) Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of the twentieth meeting of the WHO Advisory Committee on Variola Virus Research and does not necessarily represent the decisions or the policies of WHO.

## Contents

<b>EXECUTIVE SUMMARY</b> .....	1
<b>MEETING PROCEEDINGS</b> .....	3
<b>Secretariat reports</b> .....	3
<b>Variola virus repository reports</b> .....	7
<b>Diagnostics</b> .....	7
<b>Antiviral agents</b> .....	9
<b>Vaccines</b> .....	10
<b>Animal models, product development and licensure</b> .....	10
<b>GENERAL DISCUSSION</b> .....	14
<b>FUTURE RESEARCH USING LIVE VARIOLA VIRUS</b> .....	17
ANNEX 1. Agenda.....	18
ANNEX 2. Research proposals for 2018 .....	21
ANNEX 3. Abstracts of presentations .....	22
ANNEX 4. List of participants .....	39



## EXECUTIVE SUMMARY

The Advisory Committee on Variola Virus Research held its twentieth meeting on 26 and 27 September 2018 at WHO headquarters in Geneva. The Committee acknowledged its role in preparing for the discussion on smallpox at the Seventy-Second World Health Assembly in May 2019 by reviewing progress on the live variola virus research agenda.

### Achievements and considerations for variola virus research

The Committee unanimously recognized the extraordinary achievements of the research using live variola virus it had authorized, and considered that it continues to meet its commitments to ensure the delivery of medical countermeasures against smallpox.

As a result of the scientific work done under its auspices, Member States now have a range of public health tools to respond to a re-emergence of smallpox, which may also benefit the diagnosis, prevention and treatment of other orthopoxvirus infections. Most attending members of the Committee considered that live variola virus is needed for further development of antiviral agents.

### Variola virus repositories

The Committee received reports on the status of the variola virus collections held at the two WHO Collaborating Centres that are authorized as repositories of variola virus, the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America, and the State Research Centre of Virology and Biotechnology (VECTOR), Koltsovo, Novosibirsk Oblast, Russian Federation. The number of stocks remained unchanged from last year in both repositories.

The reports of the respective repository inspections in the 2016-2017 cycle have been published. For the next cycle, inspections are planned for VECTOR in January 2019 and for CDC in May 2019.

### Global health security

The Committee was informed that the WHO Smallpox Vaccine Emergency Stockpile remained unchanged in size and composition from the previous year and that the Secretariat was planning simulation exercises to test the procedures for the emergency use of smallpox vaccines.

The Committee acknowledged the establishment of the WHO Strategic and Technical Advisory Group for Infectious Hazards, whose remit included diseases that could threaten global health security, such as smallpox. The Committee appreciated receiving information on a monkeypox outbreak in Nigeria, as smallpox medical countermeasures could be relevant for monkeypox control.

### Research update

The Committee received detailed updates on the progress of previously approved research using live variola virus. Ten research proposals had been received in 2018 from the two WHO Collaborating Centres authorized to hold variola virus. The Committee suggested that the work for one of the projects be undertaken collaboratively by the two Collaborating Centres.

#### *Diagnostics*

Researchers at VECTOR reported on development and use of a new multiplex real-time PCR technique and reagent kit for species-specific identification of human pathogenic orthopoxviruses and described investigation of variola virus strains from geographical regions not previously studied.

CDC researchers reported the development of multiplexed assays specific for variola virus for application in automated diagnostic platforms for use in remote areas and protein-based tests for variola virus. CDC was collaborating with partners in the Democratic Republic of the Congo on the field application of a commercial assay to detect monkeypoxvirus.

#### *Antiviral agents*

The Committee received updates on research on antiviral agents. An oral formulation of tecovirimat was approved for treatment of smallpox by the US Food and Drug Administration (FDA) in July 2018. The manufacturer was also developing an intravenous formulation.

Researchers at VECTOR continue to develop NIOCH-14, a compound that is structurally similar to tecovirimat, as well as a range chemical compounds and monoclonal antibodies.

Researchers at CDC are investigating monoclonal antibodies and mixtures thereof to neutralize variola virus in vitro and undertaking post-exposure prophylaxis efficacy studies in animals. CDC researchers are assessing the usefulness of humanized mice for evaluating anti-variola virus agents.

The manufacturer of brincidofovir reported progress on development of this an agent that acts against variola virus by a different mechanism to that of tecovirimat. It is available in liquid and tablet form, with an intravenous formulation in development. The activity profile of this antiviral includes inhibition of orthopoxvirus replication.

#### *Vaccines*

With regard to vaccines, researchers at VECTOR had engineered a strain of vaccinia virus that was more immunogenic than the parent strain and led to reduced reactogenicity.

Researchers at both CDC and VECTOR have been investigating the neutralizing activity of sera of vaccinated subjects and animals, with CDC optimizing an assay to support vaccine studies.

A non-inferiority trial of two smallpox vaccines suggested that the MVA vaccine may be used in some subjects for whom ACAM2000 may pose some residual risk.

Following a transfer of business in Japan, the new manufacturer of the third-generation smallpox vaccine LC16m8 assured the Committee that it would continue producing vaccine for national and WHO stockpiles.

#### *Approval of smallpox countermeasures*

An overview was given of FDA's role in the development of smallpox medical countermeasures for approval, licensure or clearance, highlighting recent landmarks including approval of a real-time PCR

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_25217](https://www.yunbaogao.cn/report/index/report?reportId=5_25217)

